NASDAQ : AVTX

Avalo Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 7.44 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 399.01M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1β-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1β, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Details

NameAvalo Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees33
Founded2011
Ipo Date2015-10-15
CeoGarry Neil
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS05338F3064
Cusip05338F306
Cik0001534120
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Dr. Garry A. Neil M.D.President, Chief Executive Officer and Director
Dr. Mittie Doyle FACR, M.D.Chief Medical Officer
Taylor BoydChief Business Officer
Dr. Solomon H. Snyder M.D.Founder and Chairman of Scientific Advisory Board
Dr. Barbara S. Slusher Ph.D.Founder and Member of Scientific Advisory Board
Christopher Ryan Sullivan CPAChief Financial Officer and Head of Investor relations
Paul C. Varki J.D., M.P.HChief Legal Officer
Ashley IvanowiczSenior Vice President of Human Resources
Dr. Dino C. Miano Ph.D.Senior Vice President of CMC and Technical Operations
Jennifer RileyChief Strategy Officer

Contact

Address1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania 19087, United States
Phone410 522 8707
Websitehttps://www.avalotx.com